Pipeline Review: Large Potential Overactive Bladder Population Beckons

22 Nov 2018

• By Emily Hayes

Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.

The late-stage pipeline for the common condition of overactive bladder may be sparse, but the early-to-mid stage pipeline holds potential for new treatment options in the future – and the population is growing.

Overactive bladder refers to the frequent need to urinate – more than eight times per day or more than once at night – and a sudden need to urinate, or urinary urgency, according to the US National Association For Continence (NAFC)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

30 Apr 2025

• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

30 Apr 2025

• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

29 Apr 2025

• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.